Elizabeth Brown

Elizabeth Brown is a Postdoctoral Scientist at the University of Oxford, affiliated with the Centre for Medicines Discovery and the Davies Group: Genomics and Clinical Genome Editing. She is also associated with Adam Wilkinson’s and James Davies’ research groups.

• Education: BA and MSci from the University of Cambridge; DPhil from the University of Oxford.

Her research focuses on genomics, clinical genome editing, and therapeutic target identification in cancers such as triple-negative breast cancer and ACVR1 mutant Diffuse Midline Glioma. She employs CRISPR, transcriptomics, and spheroid-based screening in her work.

Elizabeth's recent publications highlight her contributions to hematopoietic stem cell differentiation (2023), Myc heterogeneity in breast cancer (2019), and open collaboration in pediatric brain tumor drug development (2019). Her work bridges molecular biology, bioengineering, and pharmacology to address rare and aggressive cancers.

She is actively developing novel protocols for ex vivo expansion of haematopoietic stem cells and their differentiation into granulocytes and monocytes. No scientific awards or formal student supervisory roles are mentioned in the provided text.